(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/231348 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2024/062462

(22) International Filing Date:
06 May 2024 (06.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23172907.0 11 May 2023 (11.05.2023) EP

(71) Applicants: **VIB VZW** [BE/BE]; Suzanne Tassierstraat 1, 9052 Gent (BE). **KATHOLIEKE UNIVERSITEIT LEUVEN** [BE/BE]; KU LEUVEN R&D, Waaistraat 6 - bus 5105, 3000 Leuven (BE). **VRIJE UNIVERSITEIT BRUSSEL** [BE/BE]; Pleinlaan 2, 1050 Brussel (BE).

(72) Inventors: **MAZZONE, Massimiliano**; c/o VIB-KU Leuven Center for Cancer Biology, Herestraat 49 - B912, 3000 Leuven (BE). **ORBAN, Marie-Pauline**; c/o VIB-KU Leuven Center for Cancer Biology, Herestraat 49 - B912, 3000 Leuven (BE). **BRUNNER, Janine**; VIB-VUB Center for Structural Biology, Pleinlaan 2, 1050 Brussel (BE). **SCHENK, Stephan**; c/o VIB-VUB Center for Structural Biology, Pleinlaan 2, 1050 Brussel (BE). **DOMBRECHT, Bruno**; c/o VIB vzw, Suzanne Tassierstraat 1, 9052 Genr (BE). **LANGENBERG, Tobias**; c/o VIB vzw, Suzanne Tassierstraat 1, 9052 Gent (BE). **CURCIO, Michele**; c/o VIB vzw, Suzanne Tassierstraat 1, 9052 Gent (BE). **HASSANZADEH GHASSABEH, Gholamreza**; c/o VIB Nanobody Core, Pleinlaan 2, 1050 Brussel (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: SLC4A4/NBCE1 INHIBITORS

(57) Abstract: The disclosure relates to the compounds selectively inhibiting Solute Carrier Family 4 member 4/ Electrogenic Sodium Bicarbonate Cotransporter 1 (SLC4A4/NBCe1). More in particular, said compounds are SLC4A4/NBCe1-inhibiting single domain antibodies, compounds comprising at least one CDR polypeptide of a SLC4A4/NBCe1-inhibiting single domain antibody, and compounds comprising a SLC4A4/NBCe1-inhibiting single domain antibody. Applications of compounds inhibiting SLC4A4/NBCe1 are likewise included.

WO 2024/231348 A1